Accordingly, it has been reported that gene expression of NLRP3 inflammasome components, pro-IL-18 and pro-IL-1β, is markedly increased in the liver of NASH patients [75,76]. This evidence concerns the gene NLRP3 and metabolic dysfunction-associated steatohepatitis.